福安药业(300194.SZ)发布上半年业绩，归母净利润1.13亿元，下降47.74%

Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company's operating revenue for the first half of 2025 was 921 million yuan, representing a year-on-year decrease of 35.76% [1] - The net profit attributable to shareholders of the listed company was 113 million yuan, down 47.74% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 104 million yuan, reflecting a year-on-year decrease of 48.84% [1] - The basic earnings per share were reported at 0.1 yuan [1]